“…However, other researchers contend that CETP has beneficial effects by facilitating cholesterol removal through the reverse cholesterol transport pathway. Although there continues to be debate on the issues surrounding CETP [ 1 , 2 , 3 , 4 , 5 ], various reversible and irreversible CETP inhibitors have already been reported [ 6 , 7 , 8 , 9 , 10 , 11 , 12 ]. Furthermore, Roche’s JTT-705 [ 10 ] and Merck’s anacetrapib [ 12 ] are both entering phase III clinical trials to treat Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease.…”